Role of PE therapy in CIDP

What is the Role of PE therapy in CIDP? 

The efficacy of PE therapy in CIDP has been confirmed in two double-blind randomized controlled studies.

With careful monitoring, benefit usually can be demonstrated within 6 weeks though improvement can be transient. PE is most commonly used in

(1) the subgroup of patients with disability requiring treatment with immediate effectiveness while prednisone therapy is initiated;

(2) patients with intermittent acute exacerbations; and (

3) patients who are refractory or intolerant of other immunosuppressive therapies or in whom such therapies present substantial risks (e.g., diabetic or immunocompromised patients).

Approximately 20% to 30% of patients with CIDP become refractory to all other therapies and are dependent on long-term intermittent PE or intravenous immunoglobulin.


Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

Scroll to Top